Details of the Drug

General Information of Drug (ID: DM7WYXJ)

Drug Name
P-1101
Synonyms
Pegylated interferon alpha (hepatitis B and C virus infection), PharmaEssentia; Pegylated interferon alpha-2b (polycythemia vera), AOP Orphan; PEG-INF-alpha (hepatitis B and C virus infection), PharmaEssentia; PEG-P-IFN-alpha-2b
Indication
Disease Entry ICD 11 Status REF
Essential thrombocythemia 3B63.1Z Phase 3 [1]
Hepatitis B virus infection 1E51.0 Phase 3 [2]
Myelofibrosis 2A20.2 Phase 2 [1]
Cross-matching ID
TTD ID
D0V8KD
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interferon-alpha 2 (IFNA2) TTSIUJ9 IFNA2_HUMAN Modulator [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Essential thrombocythemia
ICD Disease Classification 3B63.1Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interferon-alpha 2 (IFNA2) DTT IFNA2 9.31E-04 0.35 2.05
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT01949805) Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera. U.S. National Institutes of Health.
3 Effects of PEG-interferon-alpha-2A on Schistosoma mansoni infection in mice. J Parasitol. 2010 Aug;96(4):703-8.